Related Experiment Video
Updated: Sep 5, 2025
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Jujuboside A Ameliorates Myocardial Apoptosis and Inflammation in Rats with Coronary Heart Disease by Inhibiting
Chunfang Hu1,2, Zhiyuan Zhang1, Guixian Song1
1Cardiovascular MedicineCardiovascular Medicine, Taizhou People's Hospital, Taizhou 225399, Jiangsu, China.
Insights
Jujuboside A (JuA) improves heart function and reduces injury in a rat model of coronary heart disease (CHD). This natural compound alleviates dyslipidemia and inflammation by inhibiting the PPAR-α pathway.
Area of Science:
- Cardiovascular Pharmacology
- Natural Product Chemistry
- Molecular Biology
Background:
- Coronary heart disease (CHD) is a leading cause of mortality, driven by atherosclerosis and characterized by myocardial ischemia and inflammation.
- Current treatments aim to manage risk factors and symptoms, but effective therapeutic strategies are still needed.
- Jujuboside A (JuA), a saponin from jujube seeds, exhibits antioxidant, anti-inflammatory, and antiapoptotic properties, suggesting potential cardiovascular benefits.
Purpose of the Study:
- To investigate the effects of Jujuboside A (JuA) on myocardial injury, dyslipidemia, and inflammation in a rat model of coronary heart disease (CHD).
- To explore the underlying molecular mechanisms by which JuA may improve CHD, focusing on the PPAR-α pathway.
Main Methods:
- A rat model of CHD was established using a high-fat diet, with groups receiving varying doses of JuA.
- Cardiac function was assessed via echocardiography, and myocardial tissue was analyzed for histopathological changes.
- Blood lipid profiles, myocardial injury markers, inflammatory cytokines (TNF-α, IL-1β, IL-6), and protein expression (Bax, Bcl-2, c-caspase-3, PPAR-α pathway components) were measured.
Main Results:
- JuA treatment significantly improved cardiac function and reduced myocardial and endothelial tissue injury in CHD rats.
- JuA therapy ameliorated dyslipidemia by lowering total cholesterol, triacylglycerol, and LDL-C, while increasing HDL-C.
- JuA suppressed cardiomyocyte apoptosis and inhibited inflammation by reducing pro-inflammatory cytokine levels and preventing p65/IκBα phosphorylation, indicating PPAR-α pathway inhibition.
Conclusions:
- Jujuboside A demonstrates significant cardioprotective effects in a rat model of CHD.
- JuA alleviates myocardial and endothelial injury, improves lipid profiles, and reduces inflammation.
- The protective mechanism likely involves the inhibition of the PPAR-α signaling pathway.
Background:
Coronary heart disease (CHD) is a chronic disease caused by atherosclerosis (AS), which can cause myocardial ischemia, hypoxia, or necrosis, seriously threatening human health. There is an urgent need for effective treatments and drugs to reduce the various risk factors for coronary heart disease and relieve symptoms of angina pectoris and myocardial infarction in patients. Jujuboside A (JuA) is a triterpenoid saponin extracted from jujube seeds, which has various biological activities such as antioxidant, anti-inflammatory, antiapoptotic, and neuroprotective effects. We study the function of JuA in myocardial injury, dyslipidemia, and inflammation in the CHD rat model, to explore its potential mechanism of improving CHD.
Methods:
A rat model of CHD was established by feeding a high-fat diet. The rats were randomly divided into 5 groups (n = 6): control group, CHD group, JuA 25 mg/kg group, JuA 50 mg/kg group, and JuA 75 mg/kg group. Echocardiography was used to detect the cardiac function parameters of rats in each group, and then, hematoxylin and eosin staining was used to assess the histopathological injury in myocardial tissues. Levels of blood lipids, myocardial injury indexes, and inflammatory factors of rats in each group were measured by biochemical tests and enzyme linked immunosorbent assay, and the levels of Bax, Bcl-2, c-caspase-3, PPAR-α, p65, p-p65, IκBα, and p-IκBα protein expression in myocardial tissues were detected by western blot.
Results:
Compared with the CHD group, JuA therapy significantly improved injury in myocardial tissue and endothelial tissue. It also strengthened cardiac function, while decreasing total cholesterol, triacylglycerol, and low-density lipoprotein cholesterol levels in the serum and increasing high-density lipoprotein cholesterol levels. In addition, JuA also restrained cardiomyocytes apoptosis and inhibited the inflammatory reaction by reducing TNF-α, IL-1β, and IL-6 expression in myocardial tissues. Furthermore, administration of JuA inhibited the activation of PPAR-α pathway by preventing the phosphorylation of p65 and IκBα in myocardial tissues of CHD rats.
Conclusion:
JuA may improve cardiac function, alleviate myocardial and endothelial injury, and also ameliorate dyslipidemia and inflammatory reaction in rats with CHD, where JuA probably plays a protective role by inhibiting the activation of PPAR-α pathway.
More Related Videos
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Coronary Artery Disease II: Pathophysiology
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:30Coronary Artery Disease I: Introduction
01:30Apoptosis
01:26Coronary Artery Disease IV: Preventive Measures